[Mdr-1 ribozyme in the reversal of multidrug resistance in human ovarian cancer].
OBJECTIVE
To study the mechanism of multidrug resistance and its reversal by mdr-1 ribozyme in human ovarian cancer.


METHODS
The expression of mdr-1 and p-glycoprotein (p-gp) was studied by confocal laser microscope (Confocal), RT-PCR and Western blot analysis in adriamycin-resistant human ovarian cancer cell line (A2780/ADM) and adriamycin-sensitive one (A2780). The mdr-1 ribozyme was transfected into the A2780/ADM by Lipofectamine 2000 to overcome the multidrug resistance in ovarian cancer.


RESULTS
The expression of mdr-1 mRNA and p-gp in A2780/ADM was significantly higher than that in A2780. The expression of mdr-1 mRNA and p-gp in A2780/ADM was lowered after being transfected by mdr-1 ribozyme.


CONCLUSIONS
Multidrug resistance of A2780/ADM, possibly being caused by overexpression of mdr-1 gene, can be partially reversed by mdr-1 ribozyme.
Department of Obstetrics & Gynecology, Tongji Hospital, Tongji Medical College, University of Huazhong Science and Technology. Wuhan 430030, China.
Xiao-kui
XK
Yang
Hui
H
Xing
Qing-lei
QL
Gao
Wei
W
Wang
Su-fang
SF
Wu
Yun-ping
YP
Lu
Shi-xuan
SX
Wang
Ding
D
Ma
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000032:analysis / Q000235:genetics*; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D016337:RNA, Catalytic / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000032:analysis
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D016337:RNA, Catalytic; D012333:RNA, Messenger